Literature DB >> 1814741

Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man.

G Cocchiara1, R Battaglia, P Pevarello, M Strolin Benedetti.   

Abstract

The purpose of this study was to compare the disposition and the metabolic pattern of Reboxetine in several species, including man. [14C]-Reboxetine was given orally to the rat, the dog, the monkey (5 mg/kg) and man (2 and 4 mg/kg). Radioactivity was eliminated both by the renal and faecal route in the rat and the dog, mainly in urine in the monkey and man. Reboxetine was extensively metabolized. A number of urinary metabolites were quantified by radio-HPLC and tentatively identified by comparison with the retention times of reference compounds. Suggested routes of metabolic transformation are: 2-O-dealkylation; hydroxylation of the ethoxyphenoxy ring; oxidation of the morpholine ring; morpholine ring-opening; and combinations of these. Metabolites were partially or completely conjugated with glucuronic acid and/or sulphuric acid.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814741     DOI: 10.1007/BF03189965

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  2 in total

1.  The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans.

Authors:  D E Case; P R Reeves
Journal:  Xenobiotica       Date:  1975-02       Impact factor: 1.908

2.  The disposition and metabolism of I.C.I. 58,834 (viloxazine) in animals.

Authors:  D E Case; H Illston; P R Reeves; B Shuker; P Simons
Journal:  Xenobiotica       Date:  1975-02       Impact factor: 1.908

  2 in total
  5 in total

Review 1.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.

Authors:  J C Fleishaker
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 3.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

4.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

5.  Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.

Authors:  Michael Gerisch; Thomas Schwarz; Dieter Lang; Gabriele Rohde; Stefanie Reif; Isabelle Genvresse; Susanne Reschke; Dorina van der Mey; Camille Granvil
Journal:  Cancer Chemother Pharmacol       Date:  2017-07-11       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.